Im R retweeted
Most viewed this week from @JAMAOnc:
Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy.
ja.ma/44fFHqa
Im R retweeted
CHIP is a common, age-related condition where mutated blood stem cells expand without causing blood disorders. CHIP raises the risk of hematological malignancies, chronic inflammatory diseases (like heart & lung disease), & lung cancer. This manuscript shows that CHIP somatic clones in blood—especially TET2 mutant ones—migrate into tumors, reshape immunity, drive progression, and promote recurrence. The ability of a somatic clonal expansion in the hematopoietic compartment, to regulate malignant progression in another tissue represents a new perspective in cancer biology. #CHIP #LCMS #cancer #biology #AACR25 nejm.org/doi/full/10.1056/NE…
Im R retweeted
CONSORT 2025 statement: updated guideline for reporting randomised trials hubs.li/Q03hMZt90
ALT Box: Summary of main changes in CONSORT 2025. Copyright: 2025 The Author(s). Published by Elsevier Ltd. CC BY 4.0
Im R retweeted
Así fue el momento en que elementos policiacos interceptaron a hombres armados en la carretera federal 307, entre Playa del Carmen y Cancún.
Más información: drvnoticias.com/enfrentamien…
Im R retweeted
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium out on The Lancet Oncology
sciencedirect.com/science/ar…
meta-analysis compared the efficacy and toxicity of isodose and dose-escalated moderately hypofractionated radiotherapy ☢️(MHFRT) 🆚 conventionally-fractionated radiotherapy (CFRT) for #ProstateCancer . 7⃣ phase 3 trials involving 5,880 patients were included. Both isodose and dose-escalated MHFRT showed similar progression-free survival to CFRT, but dose-escalated MHFRT was associated with increased gastrointestinal toxicity and worse patient-reported bowel quality of life.
Isodose MHFRT did not increase genitourinary or gastrointestinal toxic effects and maintained patient-reported quality of life.
Based on these findings, isodose regimens, like 60 Gy in 20 fractions, are recommended as the standard for localized prostate cancer.
@AmarUKishan
@yilun_sun
@alison_tree
@DearnaleyProf
@ProfCatton
@ASTRO_Chair
@felixfengmd
@DrPaulNguyen
@EricMHorwitzMD
@DrSpratticus
Ping
@OncoAlert 🚨 @nataliagandur @bavilima @Silke_Gillessen @AOmlin
Im R retweeted
THROMBOCYTOPENIA (TP) CLASSIFICATION
Mechanistic classification (production, destruction, sequestration) has poorly discrimination since most causes fall under destruction.
The best way to approach TP is based on clinical context: where/how is the patient presenting?
Im R retweeted
Another nice slide by @BourlonMaite . Useful in clinics. Time off systemic therapy for major surgical intervention in advanced RCC . Note that Cabozantinib Needs to stop 3 weeks before surgery and Lenvatinib needs to stop one week before surgery. @ASCO #GU25.
Im R retweeted
🌟📢🔝🔝🔝🎓 @ASCO #GU25 | Adjuvant Therapy in RCC: A Practical Guide
Presented by: @AlbigesL, @GustaveRoussy
@OncoAlert
🔹 👏👏👏🔝Exceptional presentation as always, providing clear guidance on adjuvant therapy in RCC!
🔹 Key insights:
✅ KEYNOTE-564 defines eligible populations for adjuvant pembrolizumab.
✅ DFS benefit observed in intermediate-high risk & M1 NED subgroups.
✅ Patient perspective matters: Overestimation of adjuvant benefits in decision-making.
✅ Real-world evidence (RW): Toxicity remains a key challenge in adjuvant ICI use.
📌 Takeaway: Patient selection and shared decision-making are crucial in adjuvant RCC therapy.
🙏 Thank you, Dr. Albiges, for this outstanding and insightful session!
👥 Tagging:
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @cdanicas @DrYukselUrun @seanmmcbride @gu_onc @declangmurphy @VincentWenxinXu @RenuEapen @kidneycan
#GU25 #KidneyCancer #RCC #AdjuvantTherapy 🚀
Im R retweeted
COSMIC-313: Final OS Analysis @AlbigesL
Cabo+Nivo+Ipi (C+N+I) maintains PFS & ORR benefits vs. Placebo+N+I in 1L IMDC intermediate/poor risk aRCC. No OS difference between arms
🧬 High M2 macrophage abundance linked to improved OS with C+N+I
#GU25 @asco #kidneycancer #cancer #oncology @dryukselurun @MikeSerzanMD @drenriquegrande @crisbergerot @reginabarcar @DRBakaloudiMD @ReneeSaliby @yekeduz_emre @neerajaiims @PGrivasMDPhD @CParkMD @OncLive @apolo_andrea @tompowles1 @Uromigos @TiansterZhang @ERPlimackMD @OncBrothers
Im R retweeted
#GU25 @asco #urothelialcancer @ERPlimackMD @MattGalsky NIAGARA
🔴 Durva/gem-cis show significang OS & EFS
🟢 Durva/Ch outperformed Ch irrespective of pCR
🟠 Control arm is not de SOC (ddMVAC)
🔵 Dr Plimack beatifully places NIAGARA in context w other trials! ypT0N0 & 2-year OS
Im R retweeted
🧬🧬ctDNA is emerging as a powerful biomarker, providing insights into tumor burden, treatment response & resistance. But one size does not fit all—test sensitivity, specificity & clinical goals matter!
🩸🩸New epigenomic tech is boosting detection accuracy.
Are we ready for a new era of liquid biopsy?
#GU25 #cancer #oncology #LiquidBiopsy @isliquidbiopsy @ChristianRolfo @UmbertoMalapel1 @ElJanLe @asco @oncoalert @MikeSerzanMD @drenriquegrande @crisbergerot @reginabarcar @DRBakaloudiMD @ReneeSaliby @yekeduz_emre @neerajaiims @DrChoueiri @PGrivasMDPhD @CParkMD @OncLive @apolo_andrea @OncoBellmunt @sonpavde @MattGalsky @tompowles1 @Uromigos @kalasri3 @TiansterZhang @AndreaNecchi @ERPlimackMD @OncBrothers
Im R retweeted
@ERPlimackMD , summarized well
about ChechMate-274 and NIAGARA trials. After neoadjuvan immünoterapy continue adjuvan immünoterapy are questionable. Risk adaptive adjuvan immünotherapy will may be standart treatment. #ASCOGU25
Im R retweeted
💡 ¿Sabías qué es la Red de Datos Oncológicos (ODN)?
Una red europea que une hospitales y centros oncológicos para compartir información basada en evidencia clínica sobre medicamentos contra el cáncer, garantizando la privacidad y calidad de los datos.
🔹 Beneficios clave:
✅ Oncólogos e investigadores acceden a datos reales sobre el uso de medicamentos, mejorando los tratamientos.
✅ Los gestores pueden desarrollar nuevos modelos de acceso a fármacos, apoyando la sostenibilidad financiera del sistema de salud.
La colaboración es clave para avanzar juntos hacia un futuro más prometedor en la lucha contra el cáncer.
📲 Para más información, visita nuestra web: mdandersonhospiten.es/invest…
#InvestigaciónOncológica #MDAndersonCancerCenterMadridHospiten
Oye @Tu_IMSS te hablan, pero escucha también @sntssjalisco !
🚩Repitan conmigo…
➕Tratar bien al médico
➕Pagar bien al médico
➕Reconocer al médico
————————————-
➕➕➕ES MAS eficiente➕➕➕
➕➕➕ES MÁS efectivo➕➕➕
..que abrir más facultades.
(PD: Hay más médicos que nunca y menos en la asistencia)
@ceem_medicina @IFMSASpain